We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Eli Lilly and (LLY - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Eli Lilly and is one of 818 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. LLY is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for LLY's full-year earnings has moved 6.14% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, LLY has gained about 27.76% so far this year. Meanwhile, the Medical sector has returned an average of 2.71% on a year-to-date basis. This means that Eli Lilly and is outperforming the sector as a whole this year.
Looking more specifically, LLY belongs to the Large Cap Pharmaceuticals industry, which includes 14 individual stocks and currently sits at #17 in the Zacks Industry Rank. Stocks in this group have gained about 5.35% so far this year, so LLY is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to LLY as it looks to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of Eli Lilly and (LLY - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Eli Lilly and is one of 818 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. LLY is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for LLY's full-year earnings has moved 6.14% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, LLY has gained about 27.76% so far this year. Meanwhile, the Medical sector has returned an average of 2.71% on a year-to-date basis. This means that Eli Lilly and is outperforming the sector as a whole this year.
Looking more specifically, LLY belongs to the Large Cap Pharmaceuticals industry, which includes 14 individual stocks and currently sits at #17 in the Zacks Industry Rank. Stocks in this group have gained about 5.35% so far this year, so LLY is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to LLY as it looks to continue its solid performance.